The appointments are part of Aurora`s continued initiative to develop a dedicated scientific division, tasked with the development and launch of new technologies and products, as well as to conduct advanced scientific research. Aurora expects that the division’s initiatives will create novel, higher-margin products and revenue streams that are safe and backed by rigorous scientific research/testing.
As the vice president of product development and regulatory affairs, Morris will be responsible for the development and market introduction of new cannabis products, as well as provide strategic, regulatory leadership on all new cannabis products.
Morris, an experienced executive in the cannabis industry since 2015, was previously part of the senior leadership team at Hydropothecary, a Quebec based licensed producer. His proven expertise in quality assurance, cannabis operations, regulatory affairs and science will prove essential in bringing new cannabis products to market efficiently and effectively. Prior to his activities in the cannabis industry, Morris had fifteen years of experience at the science and policy interface, working on high-profile risk issues within the Canadian Federal Government. He has heldsenior positions and/or executive appointments at the Canadian Food Inspection Agency, Public Health Agency of Canada, Natural Resources Canada and Treasury Board Secretariat, where he advised cabinet on regulatory issues. Morris holds a doctorate from the National University of Ireland in biotechnology and publishes/lectures widely on regulation, risk and policy.
As the vice president of research, Narine will be leading Aurora Cannabis’ research innovation and researchpartnerships portfolios. Her work will be focused on human health outcomes, product safety, plant biotechnology, and early product development & testing. Narine has expertise in successfully translating promising research into positive human health outcomes. Her appointment and the initiatives that the company intends on undertaking will drive the development of a significant pipeline of science-based and -backed offerings, which management believes will resonate strongly with the large and rapidly growing domestic and international cannabis markets.
Narine received her PhD in Medical Genetics from the University of Alberta where she studied molecular and cellular changes in pathways of carcinogenesis. Afterward, she worked in the life sciences industry in Edmonton in the areas of clinical affairs and quality assurance. Transitioning back into academia at the University of Alberta, Narine managed two province-wide interdisciplinary research and education programs, the first in cardiology and the subsequent program in oncology. Most recently, she was the director of operations for two translational science Institutes at the University of Alberta.
“These key appointments reflect our commitment to a science-based approach to innovation, product and technology development,” says Terry Booth, CEO of Aurora Cannabis. “Our intention is to develop a strong pipeline of new, higher-margin revenue streams to capitalize on the tremendous opportunity in the medical cannabis and adult consumer use markets. Science and innovation are cornerstones of our global growth strategy, and with Shane and Kelly we now have highly experienced leadership for the science division. Furthermore, once completed, the CanniMed acquisition will provide a strong foundation to build our medical science division on, and help further differentiate and diversify our product offering.”